189152-96-3

Upstream product

• 161692-28-0 (4R,5R,6S,8R)-p-nitrobenzyl-3-(diphenylphosphoryloxy)-4-methyl-6-(1-(trimethylsilyloxy)ethyl)-7-oxo-1-azabicyclo<3.2.0>hept-2-ene-2-carboxylate 
• 161681-83-0 4-(4-hydroxymethylphenyl)-2-mercaptothiazole 
• 189152-68-9 C₁₆H₁₅NO₆S₂ 
• 189152-70-3 Thiocarbonic acid O-ethyl ester S-[4-(4-hydroxymethyl-phenyl)-thiazol-2-yl] ester 
• 189152-64-5 4-(2-mercaptothiazol-4-yl)benzoic acid 
• 586-89-0 4-acetyl-benzoic acid 
• 20099-90-5 4-(2-bromoacetyl)benzoic acid 

Relevant academic research and scientific papers

Synthesis and biological properties of a new series of anti-MRSA β-Lactams; 2-(thiazol-2-ylthio)carbapenems

A series of 1β-methylcarbapenems containing variously C-2 substituted thiazol-2-ylthio groups were synthesized, and their in vitro anti-MRSA activity was examined. Among them, 1β-methyl-2-(4-arylthiazol-2-ylthio) carbapenems exhibited superior anti-MRSA activity. Introduction of a cationic moiety in the C-2 side chain not only reduced the binding to HSA but also increased the stability against DHP-I, without affecting the anti-MRSA activity. It was also found that the distance between the cationic moiety and the carbapenem skeleton was related to the strength of HSA binding and the stability against DHP-I.